lorazepam has been researched along with rifampin in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (12.50) | 18.2507 |
| 2000's | 4 (50.00) | 29.6817 |
| 2010's | 3 (37.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Strassburg, CP; Tukey, RH | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bachmann, KA; Jauregui, L | 1 |
| Cho, JY; Chung, JY; Jang, IJ; Jung, HR; Kim, JR; Lim, KS; Shin, SG; Yu, KS | 1 |
2 review(s) available for lorazepam and rifampin
| Article | Year |
|---|---|
Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
Topics: Autoimmunity; Chromosome Mapping; Glucuronides; Glucuronosyltransferase; Humans; Hyperbilirubinemia; Neoplasms; Steroids; Terminology as Topic | 2000 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for lorazepam and rifampin
| Article | Year |
|---|---|
Use of single sample clearance estimates of cytochrome P450 substrates to characterize human hepatic CYP status in vivo.
Topics: Administration, Oral; Adult; Antipyrine; Aryl Hydrocarbon Hydroxylases; Carbamazepine; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Ethosuximide; Humans; Liver; Lorazepam; Male; Oxidoreductases, N-Demethylating; Phenobarbital; Phenytoin; Quinidine; Rifampin; Smoking; Theophylline; Valproic Acid | 1993 |
5 other study(ies) available for lorazepam and rifampin
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Effect of the UGT2B15 genotype on the pharmacokinetics, pharmacodynamics, and drug interactions of intravenous lorazepam in healthy volunteers.
Topics: Adult; Drug Interactions; Enzyme Inhibitors; Female; Genotype; Glucuronosyltransferase; Humans; Hypnotics and Sedatives; Infusions, Intravenous; Lorazepam; Male; Polymorphism, Genetic; Rifampin; Valproic Acid | 2005 |